Mehmet Erdem ÇAKMAK

SİGARA BIRAKMA POLİKLİNİĞİMİZE BAŞVURAN CEZAEVİ HASTALARINDA BUPROPİON VE VARENİKLİN TEDAVİSİNİN DEĞERLENDİRİLMESİ

Giriş: Bu çalışmada sigara bırakma polikliniğimize başvuran cezaevi hastalarında bupropion ve vareniklin tedavisinin etkinliğini değerlendirmeyi amaçladık. Gereç ve Yöntem: Ocak 2014-Aralık 2015 tarihleri arasında sigara bırakma polikliniğimize başvuran 108 erkek cezaevi hastası çalışmaya dahil edildi. Sayısal veriler için tanımlayıcı istatistikler (ortalama ± std. sapma), kategorik değişkenler için frekans dağılımları kullanıldı. İki kategorik değişken arasındaki ilişki değerlendirilirken ise ki kare testi kullanıldı. Bulgular: Toplam 108 erkek cezaevi hastası çalışmaya dahil edildi. Hastaların yaş ortalaması 32,05 ± 9,792 saptandı. Sigara kullanımı ortalama 22,13 ± 13,583 paket yıldı. Vareniklin kullananların %26,1i, bupropion kullananların ise %21i tedavi sonunda sigarayı bıraktı. Uygulanan ki kare analizi sonucunda kullanılan ilaç ile tedavi sonunda sigara bırakma durumu arasında istatistiksel olarak anlamlı ilişki saptanmadı. Tartışma: Çalışmamızda bupropion ve vareniklin tedavisi başlanan cezaevi hastalarında bir yıllık süreç sonunda sigara bırakma oranlarını benzer saptadık.

Anahtar Kelimeler:

Cezaevi hastaları, sigara bırakma, bupropion, vareniklin

EVALUATION OF BUPROPION AND VARENICLINE TREATMENT IN PRISON PATIENTS WHO APPLY TO OUR SMOKING CESSATION POLICLINIC

Introduction: In this study, we aimed to evaluate the efficacy of bupropion and varenicline treatment in prison patients who applied to our smoking cessation clinic. Material and Methods: Between January 2014 and December 2015, 108 male prisoners who participated in our smoking cessation clinic were included in the study. Descriptive statistics (mean ± std deviation) for numerical data and frequency distributions for categorical variables were used. When the relationship between two categorical variables was evaluated, the chi square test was used. Results: A total of 108 male prisoners were involved in the study. The mean age of the patients was 32,05 ± 9,792. The average smoking rate was 22,13 ± 13,583 packaged years. 26.1% of those using varenicline and 21% of those using bupropion left the cigarette at the end of treatment.There was no statistically significant relationship between the drug used and the smoking cessation status as a result of the applied chi square analysis at the end of the treatment. Discussion: In our study, smoking cessation rates were similar bupropion and varenicline treatment in prison patients after one year.

Keywords:

Prison patients, smoking cessation, bupropion, vareniklin,

PDF

___

1. WHO Report on the Global Tobacco Epidemic, 2008: The MPOWER Package. Geneva, World Health Organization, 2008. / DSÖ Küresel Tütün Salgını Raporu, 2008: MPOWER – KUVVET- Paketi. (Bilir N –Çev Ed.), Cenevre, Dünya Sağlık Örgütü, 2008.
2. Solak ZA, Göksel T, Erdinç E, Üstün H. Sigara ile ilişkili ciddi akciğer hastalığı olanların sigara içen yakınlarında sigara bırakma tedavisinin başarısı. Toraks Dergisi 2002; 3(3): 248-52
3. Dale LC, Ebbert JO, Hays JT, Hurt RD. Treatment of nicotine dependence. Mayo Clin Proc 2000; 75: 1311-6.
4. A US Public Health Service Report. A clinical practice guideline for treating tobacco use and dependence. JAMA 2000; 283: 3244-54.
5. West R, Mc Neill A, Raw M. Smoking cessation guidelines for health professionals: An update. Thorax 2000; 55: 987-99.
6. Smoking Cessation Clinical Practice Guideline Panel and Staff. The Agency for Health Care Policy and Research Smoking Cessation Clinical Practice Guideline. JAMA 1996; 175: 1270-80
7. Raw M, McNeill A, West R. Smoking cessation guidelines for health professionals. Thorax 1998; 53: 1-19
8. Rigotti NA. Treatment of tobacco use and dependence. N Engl J Med 2002; 346: 506-12
9. Hurt RD, et al. A comparison of sustainedrelease bupropion and placebo for smoking cessation. N Engl J Med 1997; 337:1195-202.
10. Eisenberg MJ, Filion KB, Yavin D, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ 2008; 15;179:135-44.
11. Jorenby DE, Hays JT, et al. Effi cacy of varenicline, an alpha4beta2nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296:56-63.
12. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained- release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296:47-55.
13. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991; 86: 1119-27.
14. Payne JP, Smith PO, McCracken LM, et al. Assessing nicotine dependence: a comparison of the Fagerström tolerence questionnaire (FTQ) with the Fagerström test for nicotine dependence (FTND) in a clinical sample. Addict Behav 1994; 19: 307-17.
15. McClave AK, McKnight-Eily LR, Davis SP, Dube SR. Smoking Characteristics of Adults With Selected Lifetime Mental Illnesses: Results From the 2007 National Health Interview Survey. Am J Public Health 2010;100(12):2464- 72.
16. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: A populationbased prevalence study. JAMA 2000;284(20):2606–10.
17. Hitsman B, Borrelli B, McChargue DE, Spring B, Niaura R. History of depression and smoking cessation outcome: a meta-analysis. J Consult Clin Psychol 2003; 71: 657–63.